Financials Fangzhou Inc.

Equities

6086

KYG3314S1066

Drug Retailers

Market Closed - Hong Kong S.E. 09:08:09 16/07/2024 BST 5-day change 1st Jan Change
4.6 HKD -4.76% Intraday chart for Fangzhou Inc. 0.00% 0.00%

Income Statement Evolution (Annual data)

Fiscal Period: December 2021 2022 2023
Net sales 1 1,759 2,204 2,434
EBITDA 1 -220.7 -123 -19.23
EBIT 1 -223.6 -126.8 -23.45
Operating Margin -12.71% -5.75% -0.96%
Earnings before Tax (EBT) 1 -304 -383.3 -196.7
Net income 1 -304 -383.3 -196.8
Net margin -17.28% -17.39% -8.08%
EPS - - -0.2642
Free Cash Flow - -14.82 30.94
FCF margin - -0.67% 1.27%
FCF Conversion (EBITDA) - - -
FCF Conversion (Net income) - - -
Dividend per Share - - -
Announcement Date 28/06/24 28/06/24 28/06/24
1CNY in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2021 2022 2023
Net Debt 1 1,302 1,640 1,815
Net Cash position 1 - - -
Leverage (Debt/EBITDA) -5.902 x -13.33 x -94.38 x
Free Cash Flow - -14.8 30.9
ROE (net income / shareholders' equity) - 25.1% 10.9%
ROA (Net income/ Total Assets) - -18.3% -2.82%
Assets 1 - 2,097 6,983
Book Value Per Share - - -2.550
Cash Flow per Share - - 0.2000
Capex 1 5.52 5.28 5.65
Capex / Sales 0.31% 0.24% 0.23%
Announcement Date 28/06/24 28/06/24 28/06/24
1CNY in Million
Estimates
  1. Stock Market
  2. Equities
  3. 6086 Stock
  4. Financials Fangzhou Inc.